CMS final rule on Medicare Advantage and Part D drug prices
The Centers for Medicare & Medicaid Services May 16 released a final rule with the intent of lowering drug prices for beneficiaries enrolled in Medicare Advantage and Part D programs. The rule finalizes language aimed at increasing transparency for Part D beneficiaries, as well as the option for MA plans to utilize step therapy for Part B drugs.
Related News Articles
Headline
The Medicare Payment Advisory Commission June 15 released its June report to Congress that estimated the association between Medicare Advantage enrollment and…
Headline
The Department of Health and Human Services Office of Inspector General June 11 released two reports on high rates of coverage denials by Medicare Advantage…
Headline
Members of Congress and hospital and health system leaders today gathered for a briefing in Washington, D.C., to discuss how payment delays in Medicare…
Headline
The Centers for Medicare & Medicaid Services May 28 issued a final rule making changes to the Increasing Organ Transplant Access Model beginning July 1.…
Perspective
Approximately 35 million Americans are enrolled in Medicare Advantage plans in 2026, and that number is expected to grow to about 45 million MA enrollees by…
Headline
The AHA May 7 wrote to House and Senate lawmakers in support of the Medicare Advantage Improvement Act (H.R. 8375/S. 4384), bipartisan and bicameral…